These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12243133)

  • 1. Depression, adherence to HAART, and survival.
    Perry S; Karasic D
    Focus; 2002 Aug; 17(9):5-6. PubMed ID: 12243133
    [No Abstract]   [Full Text] [Related]  

  • 2. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of depression in predicting antiretroviral adherence in Ugandan parents and their children initiating HAART in the MTCT-plus family treatment model: commentary on Jayne Byakika-Tusiime et al. 2009.
    Nakimuli-Mpungu E; Musisi S
    AIDS Behav; 2009 Oct; 13(5):969-72. PubMed ID: 19662522
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Take HAART: medication adherence in the era of highly active antiretroviral therapy.
    Allardice K
    Aust Nurs J; 2002 Apr; 9(9):19-21. PubMed ID: 12017049
    [No Abstract]   [Full Text] [Related]  

  • 6. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.
    Ammassari A; Antinori A; Aloisi MS; Trotta MP; Murri R; Bartoli L; Monforte AD; Wu AW; Starace F
    Psychosomatics; 2004; 45(5):394-402. PubMed ID: 15345784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence in antiretroviral therapy: a review of qualitative studies.
    Vervoort SC; Borleffs JC; Hoepelman AI; Grypdonck MH
    AIDS; 2007 Jan; 21(3):271-81. PubMed ID: 17255734
    [No Abstract]   [Full Text] [Related]  

  • 8. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of adherence management in human immunodeficiency virus pharmacotherapy.
    Park-Wyllie LY; Phillips EJ
    Can J Clin Pharmacol; 2003; 10(4):189-95. PubMed ID: 14712324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of depression on HIV outcomes in the HAART era.
    Hartzell JD; Janke IE; Weintrob AC
    J Antimicrob Chemother; 2008 Aug; 62(2):246-55. PubMed ID: 18456650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients.
    Dalessandro M; Conti CM; Gambi F; Falasca K; Doyle R; Conti P; Caciagli F; Fulcheri M; Vecchiet J
    J Clin Psychopharmacol; 2007 Feb; 27(1):58-61. PubMed ID: 17224714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of anger in adherence to highly active antiretroviral treatment in patients infected with HIV.
    Leombruni P; Fassino S; Lavagnino L; Orofino G; Morosini P; Picardi A
    Psychother Psychosom; 2009; 78(4):254-7. PubMed ID: 19468260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence in clinical trials and in clinical practice.
    Walsh JC
    Antivir Ther; 1999; 4 Suppl 3():49-54. PubMed ID: 16021871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep disturbance and depression as barriers to adherence.
    Phillips KD; Moneyham L; Murdaugh C; Boyd MR; Tavakoli A; Jackson K; Vyavaharkar M
    Clin Nurs Res; 2005 Aug; 14(3):273-93. PubMed ID: 15995155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treating the psychological problems first! Patients with depression don't comply with therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():103. PubMed ID: 11373761
    [No Abstract]   [Full Text] [Related]  

  • 17. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.
    Zorrilla CD; Santiago LE; Knubson D; Liberatore K; Estronza G; Colón O; Acevedo M
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1187-92. PubMed ID: 14983985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment adherence and its correlates in Addis Ababa, Ethiopia.
    Tadios Y; Davey G
    Ethiop Med J; 2006 Jul; 44(3):237-44. PubMed ID: 17447389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant treatment may improve adherence. Routine depression screening recommended.
    AIDS Alert; 2005 Jul; 20(7):80-1. PubMed ID: 16110561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.